The immuno-behavioural covariation associated with the treatment response to bumetanide in young children with autism spectrum disorder.

This study looked at how well bumetanide (a medication) worked for 79 children with autism over 3 months. Researchers found that changes in certain immune system proteins were linked to how much children's autism symptoms improved. They discovered three groups: children who responded really well (21%), those who didn't respond much (23%), and those with medium improvement (56%). Measuring immune markers before treatment helped predict which children would respond best to the medication.

This study examined 79 children with autism spectrum disorder receiving bumetanide treatment over 3 months to understand how immune system markers relate to treatment response. Researchers identified a connection between symptom improvements on the Childhood Autism Rating Scale (CARS) and changes in specific cytokines (immune system proteins). Three distinct response groups emerged: best responders (21.5%) with substantial improvement, least responders (22.8%) with minimal improvement, and medium responders (55.7%) with moderate improvement. Including baseline cytokine levels significantly improved prediction of best responders compared to models without immune markers.

The findings suggest immune responses may interact with bumetanide's mechanism to enhance GABA function in autism.

Cytokine measurements may help identify children most likely to respond to bumetanide before treatment begins. This could reduce trial-and-error approaches and improve treatment outcomes. However, further validation studies are needed before clinical implementation of immune-based predictive models.

Study design not clearly specified. Sample size relatively small for subgroup analyses. Validation in independent samples needed. Mechanism of immune-GABA interaction remains unclear. Long-term effects and safety not assessed.

Bumetanide, a drug being studied in autism spectrum disorder (ASD) may act to restore gamma-aminobutyric acid (GABA) function, which may be modulated by the immune system. However, the interaction between bumetanide and the immune system remains unclear. Seventy-nine children with ASD were analysed from a longitudinal sample for a 3-month treatment of bumetanide. The covariation between symptom improvements and cytokine changes was calculated and validated by sparse canonical correlation analysis.

Response patterns to bumetanide were revealed by clustering analysis. Five classifiers were used to test whether including the baseline information of cytokines could improve the prediction of the response patterns using an independent test sample. An immuno-behavioural covariation was identified between symptom improvements in the Childhood Autism Rating Scale (CARS) and the cytokine changes among interferon (IFN)-γ, monokine induced by gamma interferon and IFN-α2. Using this covariation, three groups with distinct response patterns to bumetanide were detected, including the best (21.5%, n = 17; Hedge's g of improvement in CARS = 2.16), the least (22.8%, n = 18; g = 1.02) and the medium (55.7%, n = 44; g = 1.42) responding groups.

Including the cytokine levels significantly improved the prediction of the best responding group before treatment (the best area under the curve, AUC = 0.832) compared with the model without the cytokine levels (95% confidence interval of the improvement in AUC was [0.287, 0.319]). Cytokine measurements can help in identifying possible responders to bumetanide in ASD children, suggesting that immune responses may interact with the mechanism of action of bumetanide to enhance the GABA function in ASD.